Last reviewed · How we verify
Lamotrigine tablets
Blocks voltage-sensitive sodium channels
Blocks voltage-sensitive sodium channels Used for Epilepsy.
At a glance
| Generic name | Lamotrigine tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Anticonvulsant |
| Target | Voltage-sensitive sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Lamotrigine is a phenyltriazine anticonvulsant that stabilizes neuronal membranes by inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
Approved indications
- Epilepsy
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Lithium Versus Lamotrigine in Bipolar Disorder, Type II (PHASE4)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Lamotrigine 25 mg Chewable Tablets, Fasting (PHASE1)
- Lamotrigine 25 mg Chewable Tablets, Non-Fasting (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions (PHASE1)
- Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions (PHASE1)
- Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study (PHASE4)
- Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |